Back to Search
Start Over
[Efalizumab. Long-term treatment of psoriasis].
- Source :
-
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete [Hautarzt] 2005 Sep; Vol. 56 (9), pp. 812-8. - Publication Year :
- 2005
-
Abstract
- Efalizumab is a humanized monoclonal CD11a-antibody. It inhibits T-cell migration and activation which are essential steps in the immunopathogenesis of psoriasis. Clinical studies have demonstrated that efalizumab is efficient and safe in the treatment of chronic plaque psoriasis. Approximately 30% of patients achieve an improvement in PASI of > or =75% within 12 weeks, with further clinical benefit noted with continued therapy. Efalizumab thus appears as an important option in the long-term management of chronic plaque psoriasis.
- Subjects :
- Antibodies, Monoclonal, Humanized
Chronic Disease
Dermatologic Agents administration & dosage
Humans
Practice Guidelines as Topic
Practice Patterns, Physicians'
Prognosis
Treatment Outcome
Antibodies, Monoclonal administration & dosage
Clinical Trials as Topic
Psoriasis drug therapy
Psoriasis epidemiology
Subjects
Details
- Language :
- German
- ISSN :
- 0017-8470
- Volume :
- 56
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
- Publication Type :
- Academic Journal
- Accession number :
- 16096737
- Full Text :
- https://doi.org/10.1007/s00105-005-1003-9